<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, Camm AJ, Ellinor PT, Gollob M, Hamilton R, Hershberger RE, Judge DP, Le Marec H, McKenna WJ, Schulze-Bahr E, Semsarian C, Towbin JA, Watkins H, Wilde A, Wolpert C, Zipes DP. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. Heart Rhythm. 2011 Aug;8(8):1308-39. [278 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21787999&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Atrial fibrillation  (427.31); Autopsy  (89.8); Cardiac arrest  (427.5); Cardiac dysrhythmia, unspecified  (427.9); Conduction disorder, unspecified  (426.9); Hypertrophic obstructive cardiomyopathy  (425.11); Long QT syndrome  (426.82); Other primary cardiomyopathies  (425.4); Other specified cardiac dysrhythmias  (427.89); Sudden infant death syndrome  (798.0)"/><FieldValue Value="MSH: Arrhythmias, Cardiac ; Arrhythmogenic Right Ventricular Dysplasia ; Atrial Fibrillation ; Autopsy ; Brugada Syndrome ; Cardiomyopathies ; Cardiomyopathy, Dilated ; Cardiomyopathy, Hypertrophic ; Cardiomyopathy, Restrictive ; Channelopathies ; Death, Sudden ; Genetic Counseling ; Genetic Testing ; Heart Arrest ; Long QT Syndrome ; Medical History Taking ; Phenotype ; Sudden Infant Death ; Tachycardia, Ventricular "/><FieldValue Value="MTH: Abnormal cardiac conduction ; Atrial Fibrillation ; Autopsy ; Brugada Syndrome (disorder) ; Cardiac Arrest ; Cardiac Arrhythmia ; Cardiomyopathies ; Cardiomyopathy, Dilated ; Conduction disorder of the heart ; Family history ; Genetic Counseling ; Genetic screening method ; Hypertrophic Cardiomyopathy ; Long QT Syndrome ; Phenotype ; Restrictive cardiomyopathy ; Sudden death ; Sudden infant death syndrome ; Tachycardia, Ventricular ; VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 1 (disorder) "/><FieldValue Value="SNOMEDCT_US: Abnormal cardiac conduction  (36358004); Arrhythmogenic right ventricular dysplasia  (253528005); Arrhythmogenic right ventricular dysplasia  (281170005); Atrial fibrillation  (49436004); Brugada syndrome  (418818005); Cardiac arrest  (397829000); Cardiac arrest  (410429000); Cardiac arrhythmia  (698247007); Cardiomyopathy  (57809008); Cardiomyopathy  (85898001); Catecholaminergic polymorphic ventricular tachycardia  (419671004); Conduction disorder of the heart  (44808001); Dilated cardiomyopathy  (195021004); Dilated cardiomyopathy  (399020009); Family history with explicit context  (57177007); Genetic counseling  (79841006); Genetic test  (405824009); Hypertrophic cardiomyopathy  (233873004); Hypertrophic cardiomyopathy  (45227007); Long QT syndrome  (9651007); Phenotype  (8116006); Postmortem examination  (168461002); Postmortem examination  (29240004); Restrictive cardiomyopathy  (415295002); Restrictive cardiomyopathy  (90828009); Sudden death  (26636000); Sudden infant death syndrome  (51178009); Ventricular tachycardia  (25569003)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Heritable channelopathies and cardiomyopathies, including:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Long QT syndrome &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Catecholaminergic polymorphic ventricular tachycardia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Brugada syndrome &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Progressive cardiac conduction disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Short QT syndrome &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Atrial fibrillation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hypertrophic cardiomyopathy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Arrhythmogenic cardiomyopathy/arrhythmogenic right ventricular cardiomyopathy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Dilated cardiomyopathy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Left ventricular noncompaction &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Restrictive cardiomyopathy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Out-of-hospital cardiac arrest &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Sudden unexpected death/sudden infant death syndrome (SUD/SIDS) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Counseling" /><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Prevention" /><FieldValue Value="Risk Assessment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Cardiology" /><FieldValue Value="Medical Genetics" /><FieldValue Value="Pediatrics" /><FieldValue Value="Preventive Medicine" /><FieldValue Value="Psychology" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /><FieldValue Value="Psychologists/Non-physician Behavioral Health Clinicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To provide the state of genetic testing for the channelopathies and cardiomyopathies &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To summarize the opinion of the international writing group members with respect to the use and role of genetic testing for these potentially heritable cardiac conditions &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Patients with channelopathies and cardiomyopathies and their families&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Genetic counseling for all patients and relatives with the familial heart disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Examination of the patient's clinical history, family history, and expressed electrocardiographic/echocardiographic phenotype &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Comprehensive genetic testing &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Targeted genetic testing &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mutation-specific genetic testing &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Post-mortem genetic testing in sudden unexpected death cases (SUD/SIDS) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Sensitivity, positive predictive value, yield, and false negative rates of genetic tests &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Signal-to-noise ratio of genetic tests &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Likelihood that a genetic test will provide diagnostic or prognostic information &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Likelihood that a genetic test will influence therapeutic choices or adoption of protective measures or lifestyle adaptations &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Likelihood that a genetic test will be harmful in diagnostic evaluation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Likelihood that a genetic test will be useful for reproductive counseling &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cost-effectiveness &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Medline and PubMed databases were searched. An initial literature search was performed in December of 2009 at the time the document writing committee was initiated. Subsequent literature searches were performed as needed throughout document development and concluded in May of 2011. All randomized and observational studies in humans were included in literature searches. Initial search terms of genetic testing &lt;span style=&quot;text-decoration: underline;&quot;&gt;and&lt;/span&gt; long QT, catecholaminergic polymorphic ventricular tachycardia, Brugada syndrome, cardiac conduction disease, short QT syndrome, atrial fibrillation, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, dilated cardiomyopathy, cardiac conduction defect, left ventricular non-compaction, restrictive cardiomyopathy, sudden unexplained death syndrome, sudden infant death syndrome; each section author was responsible for adding search criteria relevant to their section.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Level of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level of Evidence A&lt;/strong&gt;: Data derived from multiple randomized clinical trials or meta-analyses.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level of Evidence B&lt;/strong&gt;: Data derived from a single randomized trial or nonrandomized studies.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level of Evidence C&lt;/strong&gt;: Only consensus opinion of experts.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This international consensus statement summarizes the opinion of the international writing group members based on their own experience and on a general review of the literature with respect to the use and role of genetic testing for these potentially heritable cardiac conditions (channelopathies and cardiomyopathies).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Writing recommendations for genetic diseases requires adaptation of the methodology normally adopted to prepare guidelines for clinical practice. Documents produced by other scientific societies have acknowledged the need to define the criteria used to rank the strength of recommendation for genetic diseases. The most obvious difference is that randomized and/or blinded studies do not exist. Instead, most of the available data are derived from registries that have followed patients and recorded outcome information. The authors of this statement have therefore defined specific criteria for Class I, Class IIa or b, and Class III recommendations and have used the conventional language adopted by the American Heart Association/American College of Cardiology/European College of Cardiology Guidelines to express each class (see the &quot;Rating Scheme for the Strength of the Recommendations&quot; field).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendations are based on consensus of the writing group following the Heart Rhythm Society's established consensus process. It is recognized that consensus does not mean unanimous agreement among all writing group members. The writing group members identified those aspects of genetic testing for which a true consensus could be found. Surveys of the entire writing group were used. The authors received an agreement that was equal to or greater than 84% on all recommendations; most recommendations received agreement of 94% or higher.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Class of Recommendation for Testing in Index Cases&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class I&lt;/strong&gt;: &quot;Is recommended.&quot; Applied for genetic testing in index cases with a sound clinical suspicion for the presence of a channelopathy or a cardiomyopathy when the positive predictive value of a genetic test is high (likelihood of positive result &amp;gt;40% and signal/noise ratio &amp;gt;10; see Table 3 in the original consensus document), AND/OR when the genetic test result provides either diagnostic or prognostic information, or when the genetic test result influences therapeutic choices according to data in Figure 1 and in Table 3 in the original consensus document.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class IIa&lt;/strong&gt;: &quot;Can be useful.&quot;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class IIb&lt;/strong&gt;: &quot;May be considered.&quot;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class III&lt;/strong&gt;: &quot;Should not&quot; or &quot;is not recommended.&quot; Applied in cases in which it was agreed that the genetic test result failed to provide any additional benefit or could be harmful in the diagnostic evaluation of patients with possible inherited heart disease.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class of Recommendation for Testing in Family Members of the Proband&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class I&lt;/strong&gt;: Genetic testing leads to the adoption of therapy/protective measures/lifestyle adaptations.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class IIa&lt;/strong&gt;: Results of genetic testing are not associated with the use of therapeutic or protective measures but the results may be useful for reproductive counseling or instances in which genetic testing is requested by the patient who wants to know his/her mutation status.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Published cost analyses were reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The class of recommendation (&lt;strong&gt;I, IIa, IIb, and III&lt;/strong&gt;) and level of evidence (&lt;strong&gt;C&lt;/strong&gt;) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;All recommendations are &lt;strong&gt;level of evidence C&lt;/strong&gt; (i.e., based on experts' opinions).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Introduction&lt;/strong&gt; &lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Genetic counseling &lt;strong&gt;is recommended&lt;/strong&gt; for all patients and relatives with the familial heart diseases detailed in the original consensus document and should include discussion of the risks, benefits, and options available for clinical testing and/or genetic testing. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment decisions &lt;strong&gt;should not&lt;/strong&gt; rely solely on his/her genetic test result but &lt;strong&gt;should be&lt;/strong&gt; based on an individual's comprehensive clinical evaluation. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It &lt;strong&gt;can be useful&lt;/strong&gt; for pre-genetic test counseling, genetic testing, and the interpretation of genetic test results to be performed in centers experienced in the genetic evaluation and family-based management of the heritable arrhythmia syndromes and cardiomyopathies described in this document. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;State of Genetic Testing for Long QT Syndrome (LQTS)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Comprehensive or LQT1-3 (&lt;em&gt;KCNQ1&lt;/em&gt;, &lt;em&gt;KCNH2&lt;/em&gt;, and &lt;em&gt;SCN5A&lt;/em&gt;) targeted LQTS genetic testing &lt;strong&gt;is recommended&lt;/strong&gt; for any patient in whom a cardiologist has established a strong clinical index of suspicion for LQTS based on examination of the patient's clinical history, family history, and expressed electrocardiographic (resting 12-lead electrocardiograms [ECGs] and/or provocative stress testing with exercise or catecholamine infusion) phenotype. (&lt;strong&gt;Class I&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Comprehensive or LQT1-3 (&lt;em&gt;KCNQ1&lt;/em&gt;, &lt;em&gt;KCNH2&lt;/em&gt;, and &lt;em&gt;SCN5A&lt;/em&gt;) targeted LQTS genetic testing &lt;strong&gt;is recommended&lt;/strong&gt; for any asymptomatic patient with QT prolongation in the absence of other clinical conditions that might prolong the QT interval (such as electrolyte abnormalities, hypertrophy, bundle branch block, etc., i.e., otherwise idiopathic) on serial 12-lead ECGs defined as QTc &amp;gt;480 ms (prepuberty) or &amp;gt;500 ms (adults). (&lt;strong&gt;Class I&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Comprehensive or LQT1-3 (&lt;em&gt;KCNQ1&lt;/em&gt;, &lt;em&gt;KCNH2&lt;/em&gt;, and &lt;em&gt;SCN5A&lt;/em&gt;) targeted LQTS genetic testing &lt;strong&gt;may be considered&lt;/strong&gt; for any asymptomatic patient with otherwise idiopathic QTc values &amp;gt;460 ms (prepuberty) or &amp;gt;480 ms (adults) on serial 12-lead ECGs. (&lt;strong&gt;Class IIb&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mutation-specific genetic testing &lt;strong&gt;is recommended&lt;/strong&gt; for family members and other appropriate relatives subsequently following the identification of the LQTS-causative mutation in an index case. (&lt;strong&gt;Class I&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;State of Genetic Testing for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Comprehensive or CPVT1 and CVPT2 (&lt;em&gt;RYR2&lt;/em&gt; and &lt;em&gt;CASQ2&lt;/em&gt;) targeted CPVT genetic testing &lt;strong&gt;is recommended&lt;/strong&gt; for any patient in whom a cardiologist has established a clinical index of suspicion for CPVT based on examination of the patient's clinical history, family history, and expressed electrocardiographic phenotype during provocative stress testing with cycle, treadmill, or catecholamine infusion. (&lt;strong&gt;Class I&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mutation-specific genetic testing &lt;strong&gt;is recommended&lt;/strong&gt; for family members and appropriate relatives following the identification of the CPVT-causative mutation in an index case. (&lt;strong&gt;Class I&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;State of Genetic Testing for Brugada Syndrome (BrS)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Comprehensive or BrS1 (&lt;em&gt;SCN5A&lt;/em&gt;) targeted BrS genetic testing &lt;strong&gt;can be useful&lt;/strong&gt; for any patient in whom a cardiologist has established a clinical index of suspicion for BrS based on examination of the patient's clinical history, family history, and expressed electrocardiographic (resting 12-lead ECGs and/or provocative drug challenge testing) phenotype. (&lt;strong&gt;Class IIa&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Genetic testing &lt;strong&gt;is not indicated&lt;/strong&gt; in the setting of an isolated type 2 or type 3 Brugada ECG pattern. (&lt;strong&gt;Class III&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mutation-specific genetic testing &lt;strong&gt;is recommended&lt;/strong&gt; for family members and appropriate relatives following the identification of the BrS-causative mutation in an index case. (&lt;strong&gt;Class I&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;State of Genetic Testing for Progressive Cardiac Conduction Disease (CDD)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Genetic testing &lt;strong&gt;may be considered&lt;/strong&gt; as part of the diagnostic evaluation for patients with either isolated CCD or CCD with concomitant congenital heart disease, especially when there is documentation of a positive family history of CCD. (&lt;strong&gt;Class IIb&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mutation-specific genetic testing &lt;strong&gt;is recommended&lt;/strong&gt; for family members and appropriate relatives following the identification of the CCD-causative mutation in an index case. (&lt;strong&gt;Class I&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;State of Genetic Testing for Short QT Syndrome (SQTS)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Comprehensive or SQT1-3 (&lt;em&gt;KCNH2&lt;/em&gt;, &lt;em&gt;KCNQ1&lt;/em&gt;, and &lt;em&gt;KCNJ2&lt;/em&gt;) targeted SQTS genetic testing &lt;strong&gt;may be considered&lt;/strong&gt; for any patient in whom a cardiologist has established a strong clinical index of suspicion for SQTS based on examination of the patient's clinical history, family history, and electrocardiographic phenotype. (&lt;strong&gt;Class IIb&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mutation-specific genetic testing &lt;strong&gt;is recommended&lt;/strong&gt; for family members and appropriate relatives following the identification of the SQTS-causative mutation in an index case. (&lt;strong&gt;Class I&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;State of Genetic Testing for Atrial Fibrillation (AF)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Genetic testing &lt;strong&gt;is not indicated&lt;/strong&gt; for atrial fibrillation at this time. (&lt;strong&gt;Class III&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Single nucleotide polymorphism (SNP) genotyping in general and SNP rs2200733 genotyping at the 4q25 locus for AF &lt;strong&gt;is not indicated&lt;/strong&gt; at this time based on the limited outcome data currently available. (&lt;strong&gt;Class III&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;State of Genetic Testing for Hypertrophic Cardiomyopathy (HCM)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Comprehensive or targeted (&lt;em&gt;MYBPC3&lt;/em&gt;, &lt;em&gt;MYH7&lt;/em&gt;, &lt;em&gt;TNNI3&lt;/em&gt;, &lt;em&gt;TNNT2&lt;/em&gt;, &lt;em&gt;TPM1&lt;/em&gt;) HCM genetic testing &lt;strong&gt;is recommended&lt;/strong&gt; for any patient in whom a cardiologist has established a clinical diagnosis of HCM based on examination of the patient's clinical history, family history, and electrocardiographic/echocardiographic phenotype. (&lt;strong&gt;Class I&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mutation-specific genetic testing &lt;strong&gt;is recommended&lt;/strong&gt; for family members and appropriate relatives following the identification of the HCM-causative mutation in an index case. (&lt;strong&gt;Class I&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;State of Genetic Testing for Arrhythmogenic Cardiomyopathy (ACM)/Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Comprehensive or targeted (&lt;em&gt;DSC2&lt;/em&gt;, &lt;em&gt;DSG2&lt;/em&gt;, &lt;em&gt;DSP&lt;/em&gt;, &lt;em&gt;JUP&lt;/em&gt;, &lt;em&gt;PKP2&lt;/em&gt;, and &lt;em&gt;TMEM43&lt;/em&gt;) ACM/ARVC genetic testing &lt;strong&gt;can be useful&lt;/strong&gt; for patients satisfying task force diagnostic criteria for ACM/ARVC. (&lt;strong&gt;Class IIa&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Genetic testing &lt;strong&gt;may be considered&lt;/strong&gt; for patients with possible ACM/ARVC (1 major or 2 minor criteria) according to the 2010 task force criteria. (&lt;strong&gt;Class IIb&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Genetic testing &lt;strong&gt;is not recommended&lt;/strong&gt; for patients with only a single minor criterion according to the 2010 task force criteria. (&lt;strong&gt;Class III&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mutation-specific genetic testing &lt;strong&gt;is recommended&lt;/strong&gt; for family members and appropriate relatives following the identification of the ACM/ARVC-causative mutation in an index case. (&lt;strong&gt;Class I&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;State of Genetic Testing for Dilated Cardiomyopathy (DCM)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Comprehensive or targeted (&lt;em&gt;LMNA&lt;/em&gt; and &lt;em&gt;SCN5A&lt;/em&gt;) DCM genetic testing &lt;strong&gt;is recommended&lt;/strong&gt; for patients with DCM and significant cardiac conduction disease (i.e., first, second, or third-degree heart block) and/or a family history of premature unexpected sudden death. (&lt;strong&gt;Class I&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Genetic testing &lt;strong&gt;can be useful &lt;/strong&gt;for patients with familial DCM to confirm the diagnosis, to recognize those who are at highest risk of arrhythmia and syndromic features, to facilitate cascade screening within the family, and to help with family planning. (&lt;strong&gt;Class IIa&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mutation-specific genetic testing &lt;strong&gt;is recommended&lt;/strong&gt; for family members and appropriate relatives following the identification of a DCM-causative mutation in the index case. (&lt;strong&gt;Class I&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;State of Genetic Testing for Left Ventricular Noncompaction (LVNC)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;LVNC genetic testing &lt;strong&gt;can be useful&lt;/strong&gt; for patients in whom a cardiologist has established a clinical diagnosis of LVNC based on examination of the patient's clinical history, family history, and electrocardiographic/echocardiographic phenotype. (&lt;strong&gt;Class IIa&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mutation-specific genetic testing &lt;strong&gt;is recommended&lt;/strong&gt; for family members and appropriate relatives following the identification of an LVNC-causative mutation in the index case. (&lt;strong&gt;Class I&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;State of Genetic Testing for Restrictive Cardiomyopathy (RCM)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;RCM genetic testing &lt;strong&gt;may be considered&lt;/strong&gt; for patients in whom a cardiologist has established a clinical index of suspicion for RCM based on examination of the patient's clinical history, family history, and electrocardiographic/echocardiographic phenotype. (&lt;strong&gt;Class IIb&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mutation-specific genetic testing &lt;strong&gt;is recommended&lt;/strong&gt; for family members and appropriate relatives following the identification of an RCM-causative mutation in the index case. (&lt;strong&gt;Class I&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;State of Genetic Testing for Out-of-Hospital Cardiac Arrest Survivors&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;In the survivor of an unexplained out-of-hospital cardiac arrest, genetic testing &lt;strong&gt;should be&lt;/strong&gt; guided by the results of medical evaluation and is used for the primary purpose of screening at-risk family members for subclinical disease. (&lt;strong&gt;Class I&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Routine genetic testing, in the absence of a clinical index of suspicion for a specific cardiomyopathy or channelopathy, &lt;strong&gt;is not indicated&lt;/strong&gt; for the survivor of an unexplained out-of-hospital cardiac arrest. (&lt;strong&gt;Class III&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;State of Post-mortem Genetic Testing in Sudden Unexplained Death (SUD) Cases (SUD/Sudden Infant Death Syndrome [SIDS])&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;For all SUDS and SIDS cases, collection of a tissue sample &lt;strong&gt;is recommended&lt;/strong&gt; (5&amp;ndash;10 mL whole blood in ethylenediaminetetraacetic acid [EDTA] tube, blood spot card, or a frozen sample of heart, liver, or spleen) for subsequent deoxyribonucleic acid (DNA) analysis/genetic testing. (&lt;strong&gt;Class I&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In the setting of autopsy-negative SUDS, comprehensive or targeted (&lt;em&gt;RYR2&lt;/em&gt;, &lt;em&gt;KCNQ1&lt;/em&gt;, &lt;em&gt;KCNH2&lt;/em&gt;, and &lt;em&gt;SCN5A&lt;/em&gt;) ion channel genetic testing &lt;strong&gt;may be considered&lt;/strong&gt; in an attempt to establish probable cause and manner of death and to facilitate the identification of potentially at-risk relatives and &lt;strong&gt;is recommended&lt;/strong&gt; if circumstantial evidence points toward a clinical diagnosis of LQTS or CPVT specifically (such as emotional stress, acoustic trigger, drowning as the trigger of death). (&lt;strong&gt;Class IIb&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mutation-specific genetic testing &lt;strong&gt;is recommended&lt;/strong&gt; for family members and other appropriate relatives following the identification of a SUDS-causative mutation in the decedent. (&lt;strong&gt;Class I&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class of Recommendation for Testing in Index Cases&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class I&lt;/strong&gt;: &quot;Is recommended.&quot; Applied for genetic testing in index cases with a sound clinical suspicion for the presence of a channelopathy or a cardiomyopathy when the positive predictive value of a genetic test is high (likelihood of positive result &amp;gt;40% and signal/noise ratio &amp;gt;10; see Table 3 in the original consensus document), AND/OR when the genetic test result provides either diagnostic or prognostic information, or when the genetic test result influences therapeutic choices according to data in Figure 1 and in Table 3 in the original consensus document.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class IIa&lt;/strong&gt;: &quot;Can be useful.&quot;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class IIb&lt;/strong&gt;: &quot;May be considered.&quot;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class III&lt;/strong&gt;: &quot;Should not&quot; or &quot;is not recommended.&quot; Applied in cases in which it was agreed that the genetic test result failed to provide any additional benefit or could be harmful in the diagnostic evaluation of patients with possible inherited heart disease.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class of Recommendation for Testing in Family Members of the Proband&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class I&lt;/strong&gt;: Genetic testing leads to the adoption of therapy/protective measures/lifestyle adaptations.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class IIa&lt;/strong&gt;: Results of genetic testing are not associated with the use of therapeutic or protective measures but the results may be useful for reproductive counseling or instances in which genetic testing is requested by the patient who wants to know his/her mutation status.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level of Evidence A&lt;/strong&gt;: Data derived from multiple randomized clinical trials or meta-analyses.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level of Evidence B&lt;/strong&gt;: Data derived from a single randomized trial or nonrandomized studies.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level of Evidence C&lt;/strong&gt;: Only consensus opinion of experts.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;All recommendations are level of evidence C (i.e., based on experts' opinions).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Appropriate use of genetic testing for the channelopathies and cardiomyopathies &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Refer to the original consensus document for diagnostic, prognostic, and therapeutic implications of specific genetic tests. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;In genetic testing, many so-called &quot;positive&quot; test results are represented by less informative deoxyribonucleic acid (DNA) variants currently annotated with the expression &quot;Variants of Uncertain Significance&quot; (VUS). Only recently is the frequency of rare VUS among otherwise healthy volunteers across the exomes of various disease-causing genes being identified. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The VUS issue and its associated possibility of a false positive genetic test results are also disease dependent, ranging from a relatively low rate of false positives for catecholaminergic polymorphic ventricular tachycardia (CPVT) testing to an alarmingly high rate of possible false positives associated with the arrhythmogenic cardiomyopathy (ACM)/arrhythmogenic right ventricular cardiomyopathy (ARVC) test. A false positive involves the identification of a rare but otherwise non-pathogenic mutation. For many disease-specific genetic tests, the false positive rate is unknown. The potential for false positive genetic test results rises significantly when genetic testing is pursued in settings in which the phenotype is ambiguous or absent, such as in screening. Consequently, there is no role for universal genetic testing for any of the diseases detailed in this statement. Instead, genetic testing must be phenotype directed. If the clinical diagnosis is in question, it may be prudent first to refer the patient to a center specializing in that particular disease rather than proceeding directly with genetic testing. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;When using or considering the guidance from this document, it is important to remember that there are no absolutes governing many clinical situations. The final judgment regarding care of a particular patient must be made by the health care provider and the patient in light of all relevant circumstances. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The broader ethical, legal, and societal implications of genetic testing are beyond the scope of the original consensus document and a variety of national regulations and specifications exist. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The genetic test result must be scrutinized with great caution, as all genetic tests are probabilistic tests rather than deterministic/binary ones. This issue of genetic test result interpretation applies to all the diseases detailed in the original consensus document. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Living with Illness" /><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, Camm AJ, Ellinor PT, Gollob M, Hamilton R, Hershberger RE, Judge DP, Le Marec H, McKenna WJ, Schulze-Bahr E, Semsarian C, Towbin JA, Watkins H, Wilde A, Wolpert C, Zipes DP. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. Heart Rhythm. 2011 Aug;8(8):1308-39. [278 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21787999&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2011 Aug" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="European Heart Rhythm Association - Professional Association" /><FieldValue Value="Heart Rhythm Society - Professional Association" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Heart Rhythm Society&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Writing Group&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Writing Group Members&lt;/em&gt;: Michael J. Ackerman, MD, PhD, Mayo Clinic, Rochester, Minnesota; Silvia G. Priori, MD, PhD, Fondazione Salvatore Maugeri University of Pavia, Pavia, Italy and New York University, New York, New York; Stephan Willems, MD, PhD, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Charles Berul, MD, FHRS, CCDS, Children's National Medical Center and George Washington School of Medicine, Washington, District of Columbia; Ramon Brugada, MD, PhD, Girona Institute of Biomedical Research and University of Girona School of Medicine, Girona, Spain; Hugh Calkins, MD, FHRS, CCDS, Johns Hopkins University, Baltimore, Maryland; A. John Camm, MD, FHRS, St. George's University of London, London, United Kingdom; Patrick T. Ellinor, MD, PhD, Massachusetts General Hospital, Cardiac Arrhythmia Service, Boston, Massachusetts; Michael Gollob, MD, University of Ottawa Heart Institute, Ottawa, Canada; Robert Hamilton, MD, CCDS, Hospital for Sick Children, Toronto, Canada; Ray E. Hershberger, MD, University of Miami Miller School of Medicine, Miami, Florida; Daniel P. Judge, MD, Johns Hopkins University, Baltimore, Maryland, Universit&amp;eacute; Paris Descartes, Paris, France; Herv&amp;egrave; Le Marec, MD, l'Institut du thorax, Nantes Cedex, Nantes, France; William J. McKenna, MD, Institute of Cardiovascular Science, University College London, London, United Kingdom; Eric Schulze-Bahr, MD, PhD, University Hospital Muenster, Muenster, Germany; Chris Semsarian, MBBS, PhD, University of Sydney, Sydney, Australia; Jeffrey A. Towbin, MD, Cincinnati Children's Hospital, Cincinnati, Ohio; Hugh Watkins, MD, PhD, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom; Arthur Wilde, MD, PhD, University of Amsterdam, Academic Medical Center, Amsterdam, The Netherlands; Christian Wolpert, MD, Ludwigsburg Clinic, Ludwigsburg, Germany; Douglas P. Zipes, MD, FHRS, Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;All members of this document-writing group provided disclosure statements of all relationships that might present real or perceptible conflicts of interest. Disclosures for the members of the task force are published in the Appendix section of the original consensus document.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="159" OrdBy="1255" ID="453" Name="Guideline Endorser(s)" Type="orglist"><FieldValue Value="American Heart Association - Professional Association" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;http://www.hrsonline.org/Practice-Guidance/Clinical-Guidelines-Documents/2011-Expert-Consensus-Statement-on-the-State-of-Genetic-Testing-for-the-Channelopathies-and-Cardiomyopathies/(search)/t&quot; title=&quot;Heart Rhythm Society (HRS) Web site&quot;&gt;Heart Rhythm Society (HRS) Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following is available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The HRS policy for development and endorsement of clinical guidance documents from HRS and others. Washington (DC): Heart Rhythm Society (HRS); 2009 Sep. 6 p. Available from the &lt;a href=&quot;http://www.hrsonline.org/content/download/1395/19446/file/HRS_Document_Endorsement_Process_Policy.pdf&quot; title=&quot;Heart Rhythm Society Web site&quot;&gt;Heart Rhythm Society Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on February 13, 2013.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This summary is based on the original guideline, which is subject to the guideline developer's restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
